Dr Bill Mezzanotte, CSL’s Head of Research and Development, said, “While we are disappointed in the outcome of the Article 20 procedure, we will respect the regulatory process and are committed to implementing it in full."

Algorae Pharmaceuticals has been announced as a founding participant and the healthcare and life sciences launch partner for the Sovereign AI Infrastructure initiative, led by AgenticScale.ai and built on NVIDIA-accelerated technology.

Avecho Biotechnology has moved a major step closer to completing its pivotal Phase 3 study of a TPM-enhanced cannabidiol capsule for insomnia after an independent Data Monitoring Board unanimously recommended that the trial continue with its originally planned enrolment of 519 participants.

INOVIQ says the findings reinforce the broader potential of its off-the-shelf cell-free CAR exosome platform, which has now shown activity in triple-negative breast cancer, non-small cell lung cancer, and ovarian cancer.

AFT Pharmaceuticals has announced that the US Food and Drug Administration has reviewed and allowed the company’s Investigational New Drug application for its injectable iron project to proceed to a global Phase 3 clinical trial.

Neurizon Therapeutics this week disclosed new preclinical data for its lead ALS candidate, NUZ-001, that the company will present at the BIO International Convention 2026.

The company presented the findings at the International Mental Health Conference on the Gold Coast and described clinically significant reductions in depression and trauma symptoms alongside improvements in quality of life and daily functioning.

MTPConnect has adopted a new name as it enters its second decade, rebranding itself as AUScelerate. The organisation said the change aims to better reflect its mission to commercialise Australian life sciences.

UniQuest and the Ellison Medical Institute have signed an exclusive licence that could push a promising University of Queensland treatment for advanced prostate cancer into first-in-human trials as early as 2027.

Recce Pharmaceuticals has received approval from the Human Research Ethics Committee to advance its Australian study of RECCE 327 Topical Gel to a pivotal Phase 3 trial for diabetic foot infections, a move the company says accelerates its global registration strategy.

Invion has taken a step to strengthen its clinical leadership by appointing Dr Colin Hopper, a globally recognised authority in photodynamic therapy, as a clinical advisor.

Tetratherix has announced that its joint venture, Tutelix, has received approval from the Human Research Ethics Committee in Australia to start an international pivotal clinical trial for its hydrogel spacer.

AusBiotech has announced that Australia's Biggest Week in Biotech 2027 will be held in Brisbane from 23–27 August, marking a shift from its traditional October timing.

Atmo Biosciences has been named a winner in Fast Company’s 2026 World Changing Ideas Awards, an annual program that recognises innovations delivering measurable impact across industries.

Racura Oncology has secured $34.3 million following a series of fundraising initiatives supported by new and existing shareholders, giving the company a strong cash balance to fully fund its RC220 clinical programs in Acute Myeloid Leukaemia, EGFRm non-small cell lung cancer and anthracycline cardioprotection in solid tumour patients.

Dr Christian Toouli, CEO and Managing Director of FivepHusion, said, "The ethics approval of the Phase II DART protocol is an exciting milestone towards our goal of evaluating Deflexifol as a promising therapy for these patients."

Dr Chris Baldwin, CEO and Managing Director, said, “Receipt of ethics approval for our KappaMab Phase 2b clinical trial in combination with pomalidomide and dexamethasone is a significant milestone for HaemaLogiX."